-
Wound care
Healing wounds remains a global healthcare challenge. Delayed wound healing creates a huge social and economic burden on society. For people living with wounds, it affects their quality of life and can lead to social isolation, anxiety, and even mortality. Treating wounds is costly with chronic wounds such as diabetic foot ulcers, venous leg ulcers, arterial ulcers and pressure ulcers persisting for years.
Many different factors delay wound healing, including excess exudate, infection and biofilms.
40%
of all wounds have excess exudate
Internet survey, Onya Therapeutics 2019
34%
of trauma wounds become infected
Military Medicine 2019; 184 Nov/Dec Suppl.
78%
of chronic wounds harbor biofilms
J Wound Care 2017; 26
To address the significant need for new therapeutics that reduce the use of antibiotics in wound care and improve patients quality of life.
Onya Therapeutics are developing a novel patented drug delivery technology and investigating compounds shown to prevent the spread of infection by attacking bacteria’s invasion and protection mechanisms.
OTX PP01
A patented, targeted release patch that utilises an established and safe active compound. The patch properties address excess wound exudate and associated complications.
OTX PP02
An adapted controlled release patch to reduce risk of infection in trauma wounds.
OTX PP03
A therapeutic targeting infected wounds, providing a topically applied, locally available, alternative to current antibiotics.
There is a significant need for new therapeutic agents to combat bacterial infection. Onya is in the early stages of pursuing quorum sensing and virulence factor inhibition, an alternative approach to preventing the spread of infection by attacking bacteria’s invasion and protection mechanisms, decreasing the effects of bacterial infection and enabling the body to recognise and overcome infection.